AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04498962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danzhu Fuyuan Granule
Description: Danzhu Fuyuan Granules，2 times / day, 1 bag / time, one time in the morning and one time in the evening. It is recommended to add the same amount of boiling water as the particles to soak for 30 seconds, and then add 5 times boiling water to dissolve until completely dissolved.The treatment cycle of each arm: 8 weeks for Chronic Stable Angina, 6 months for Vascular Dementia and 6 months for Idiopathic Membranous Nephropathy.
Study NCT03636750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB002.1T
Description: HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy
Study NCT00612300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lokomat - Physical therapy
Description: A: Lokomat training, 30 minutes per day for 3 weeks, 5 days per week. B: Categorized gait training by physical therapist, 30 minutes per day for 3 weeks, 5 days per week
Study NCT00612300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy - Lokomat
Description: B: Daily 30 minutes of gait training with a physical therapist, 5 days per week for 3 weeks.~A: Daily 30 minutes of Lokomat training, 5 days per week for 3 weeks.
Study NCT02364674 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Resolution Computed Tomography scan
Description: a HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1.
Study NCT04019158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset
Description: All participants will walk in the three conditions described earlier in this form
Study NCT01389297 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMART Recovery face-to-face meetings
Description: Attending these meetings at least weekly in frequency
Study NCT01389297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Recovery face-to-face meetings
Description: Attending these meetings at least weekly in frequency
Study NCT01389297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overcoming Addictions web application
Description: Logging into and using the web application at least weekly during the course of the study
Study NCT03060772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Participants will take 30 mg of pioglitazone once daily for a total of two to four weeks for those randomized to therapy, until the next bronchoscopy is performed. Participants will receive 14 to 28 tablets of active pioglitazone, which is enough to complete the minimum 14-day course of therapy.
Study NCT03012854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: short-myotomy
Description: 1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length less than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.
Study NCT03012854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long-myotomy
Description: 1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.
Study NCT03012854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full-thickness myotomy
Description: 1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.
Study NCT03012854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: circular myotomy
Description: 1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.
Study NCT03096522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin 2% spray
Description: Patients will undergo anal fistulotomy then they will use phenytoin 2% spray topically on the anal wound resulting from fistulotomy with each sitz bath (twice per day) untill the anal wound heals completely
Study NCT03096522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal fistulotomy
Description: Probing of the fistula tract followed by lay open of the tract and curettage of granulation tissue in its base
Study NCT02863835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EIT
Description: All participants will have continuous monitoring of EIT whilst self venting
Study NCT02863835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salbutamol nebulisation and with CPAP
Description: All participants will have continuous monitoring - salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure during this time.
Study NCT00783042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
Study NCT00783042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral, once daily for 1 month (double blind)
Study NCT02383446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elan foot prosthesis
Description: The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
Study NCT01567488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10mg/day
Study NCT01567488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide LAR
Description: 30 mg each 28 days
Study NCT01849588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study NCT02784301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belly breathing with biofeedback app
Description: This intervention consists of learning how to belly breathe using a smartphone biofeedback application that coaches children how to breathe slowly and deeply. The app consists of a cartoon avatar in a hot air balloon that inhales and exhales bubbles. The goal of the biofeedback game is to a) teach a voluntary deep breathing protocol, b) detect compliance to the breathing protocol using the attached audio-based pulse oximeter sensor and c) to raise the hot air balloon in accordance to this compliance in order to motivate the children. Scenery changes as the balloon rises, driven by biofeedback, until it eventually reaches outer space.
Study NCT03479515 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound, ADP, bioimpedance measurements
Study NCT04558515 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Novel malaria diagnostics & tools
Description: Next generation microscopy tools for malaria diagnosis and medical applications
Study NCT02784301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Belly breathing without biofeedback app
Description: This intervention consists of learning how to belly breathe without the biofeedback application prior to the blood collection and continuing with self-directed belly breathing during the procedure itself.
Study NCT02784301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Belly breathing + visual distraction
Description: This intervention consists of learning how to belly breathe without the application plus receiving visual distraction by watching a cartoon avatar in the hot air balloon rising through space. The avatar will not coach the child to breathe as the visual cues for breathing (words and bubbles) will not be present and the avatar will not rise in response to correct belly breathing. Participants will be instructed to continue with self-directed breathing while also watching the visual distraction during the blood collection procedure.
Study NCT02871375 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A multifocal contact lenses
Description: Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)
Study NCT02871375 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual multifocal contact lenses
Description: Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality
Study NCT02850874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy
Description: HIPEC in this study involves the washing of the peritoneal cavity with a heated (40-48°C), (1000 mg/m sq) solution of gemcitabine in 1.5% dextrose for 90 min. Compared with systemic delivery of chemotherapy, intraperitoneal delivery can increase site-specific concentration of chemotherapeutic agents and decrease duration of perfusion, vascular complications, and systemic toxicity. The use of heated chemotherapeutic agents, compared to conventional protocols, has been shown to increase direct cytotoxicity to malignant cells and augment penetration into tumors.
Study NCT02850874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open pancreaticoduodenectomy
Description: Tumors of the pancreatic head will be surgically removed by open PD (standard and pylorus-preserving approaches) with the aim of achieving en bloc R0 tumor resection (no macroscopic residual cancer remaining). In all patients, a lymphadenectomy will be performed along the hepatoduodenal ligament, common hepatic artery, vena cava, and the interaortocaval and right side of the superior mesenteric artery. In cases with portal vein involvement, a venous resection will be performed to achieve R0 resection. Patients with arterial infiltration by the tumor will be deemed locally nonresectable and will be excluded from analysis.~Established, routine surgical and ERAS protocols will be followed for pre-, intra-, and postoperative care of patients. Patients will be discharged after postoperative day 5 if tolerating oral intake and showing no signs or symptoms of complications.
Study NCT02850874 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open pancreaticoduodenectomy
Description: Tumors of the pancreatic head will be surgically removed by open PD (standard and pylorus-preserving approaches) with the aim of achieving en bloc R0 tumor resection (no macroscopic residual cancer remaining). In all patients, a lymphadenectomy will be performed along the hepatoduodenal ligament, common hepatic artery, vena cava, and the interaortocaval and right side of the superior mesenteric artery. In cases with portal vein involvement, a venous resection will be performed to achieve R0 resection. Patients with arterial infiltration by the tumor will be deemed locally nonresectable and will be excluded from analysis.~Established, routine surgical and ERAS protocols will be followed for pre-, intra-, and postoperative care of patients. Patients will be discharged after postoperative day 5 if tolerating oral intake and showing no signs or symptoms of complications.
Study NCT02850874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Neoadjuvant and adjuvant systemic chemotherapy will be administered to all PDAC patients with the aim of diminishing the tumor burden and maximizing the chance of complete surgical resection. Gemcitabine (GEMZAR®) will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional guidelines for dosing, frequency, duration, administration route, and setting.
Study NCT02850874 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Neoadjuvant and adjuvant systemic chemotherapy will be administered to all PDAC patients with the aim of diminishing the tumor burden and maximizing the chance of complete surgical resection. Gemcitabine (GEMZAR®) will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional guidelines for dosing, frequency, duration, administration route, and setting.
Study NCT03460522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: Patients will receive standard of care chemotherapy (only maintenance) after Inotuzumab Ozogamicin.
Study NCT03192839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose PUFA
Description: Low dose PUFA
Study NCT03192839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dose PUFA
Description: High dose PUFA
Study NCT03192839 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03592121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-101
Description: Apply approximately 1 hour prior to sexual activity
Study NCT03592121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Apply approximately 1 hour prior to sexual activity
Study NCT00004412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine Butyrate
Description: To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.
Study NCT00004412 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Arginine Butyrate
Description: To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.
Study NCT00004412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard local care dressing
Description: To heal leg ulcers.
Study NCT00004412 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard local care dressing
Description: To heal leg ulcers.
Study NCT03501732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values Affirmation
Description: Experimental Group selects two values and describes why they are important
Study NCT03501732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk Feedback
Description: Experimental and comparator conditions both receive normative feedback in domains of risk
Study NCT03501732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Feedback
Description: Experimental and comparator conditions both receive normative feedback in domains of risk
Study NCT00268918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants may continue receiving study drug as long as their disease does not worsen
Study NCT00268918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787
Description: Participants may continue receiving study drug as long as their disease does not worsen
Study NCT04410718 — intervention group
Intervention type: OTHER
Intervention: Glycaemic levels
Description: Glycaemic levels during admission for COVID-19
Study NCT00313417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate
Description: Up to 10 grams
Study NCT00313417 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in the same way and appearance as the active treatment
Study NCT04327102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education tools combined with health literacy intervention
Description: On the basis of the control group, the intervention measures to improve the health literacy of patients were implemented and self-made health education tools were used. During hospitalization, health knowledge lectures shall be organized for patients. Before the activity, the theme of the activity shall be clarified. Each participant shall be organized by the educator to sit on the tool chart in a U-shape. According to the theme of the tool map, patients interact with educators. And learn the knowledge content related to hypertension health literacy. Before the end of the activity, the educator will review all the contents discussed in the activity quickly, answer the questions in the activity, and help the participants to sort out and consolidate the knowledge acquired in the education. Follow up intervention for patients after leave hospital.
Study NCT02637583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Intramuscular injection of 13-valent pneumococcal conjugate vaccine once
Study NCT02637583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Intramuscular injection of 13-valent pneumococcal conjugate vaccine once
Study NCT02637583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: Intramuscular injection of 23-valent pneumococcal polysaccharide vaccine once
Study NCT02637583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPV23
Description: Intramuscular injection of 23-valent pneumococcal polysaccharide vaccine once
Study NCT04851626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnotic intervention for persistent pelvic pain.
Description: Education about persistent pelvic pain followed by 7 recordings of hypnosis intervention across 7 weeks accessed online through recordings.
Study NCT04851626 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group persistent pelvic pain no intervention.
Description: Control group no hypnotic intervention. Waitlist control.
Study NCT02893241 — intervention group
Intervention type: DRUG
Intervention: Cafedrine/theodrenaline
Study NCT02893241 — intervention group
Intervention type: DRUG
Intervention: Ephedrine
Study NCT04531761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Support Program
Description: The parent support program includes three modules aimed at increasing knowledge, positive attitudes, and supportive behaviors towards trans youth. Each online module includes several activities including writing prompts, videos, interactive quizzes, and other educational activities.
Study NCT05076201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patients with completed rehab
Description: The main objective is to measure the level of cocaine craving, 6 months after the end of their detoxification treatment (outpatient or full hospitalization), in patients with a diagnosis of moderate to severe dependence (DSM 5) to cocaine and co-addiction, or not, to alcohol and / or psychostimulants. To evaluate cocaïne craving,the questionnaire CCQ-Brief will be used.
Study NCT02300363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (rosuvastatin)
Description: 10 mg rosuvastatin administered on Day 1 and Day 13
Study NCT02300363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (LX4211)
Description: 400 mg LX4211 administered on Day 7 through Day 13
Study NCT02300363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)
Description: 10 mg rosuvastatin + 400 mg LX4211 administered concomitantly on Day 13
Study NCT00117143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered subcutaneously on day 1 and on day 15 or 22 if the platelet count was ≤ 50 x 10⁹/L and not rising, peak platelet count was ≤ 450 x 10⁹/L and no serious adverse events related to treatment were observed.
Study NCT02142530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study NCT02142530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Study NCT03872180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV
Study NCT03872180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT03872180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT04262336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DB-020
Description: Injectable sterile viscous solution of DB-020 and sodium hyaluronate in sterile water
Study NCT04262336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Injectable sterile viscous solution of sodium hyaluronate in sodium chloride